Rettig, E. M. & D’Souza, G. Epidemiology of head and neck cancer. Surg. Oncol. Clin. 24, 379–396 (2015).
Getz, K. R. et al. Statin use and head and neck squamous cell carcinoma outcomes. Int. J. Cancer 148, 2440–2448 (2021).
Bourguillon, R. O., Stokes, W. A., Dorth, J. & Schmitt, N. C. Repurposing statin drugs to decrease toxicity and improve survival outcomes in head and neck cancer. OTO Open 5, 2473974X211065715 (2021).
Argiris, A., Karamouzis, M. V., Raben, D. & Ferris, R. L. Head and neck cancer. Lancet 371, 1695–1709 (2008).
Vigneswaran, N. & Williams, M. D. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac. Surg. Clin. 26, 123–141 (2014).
Lang, J. et al. Comprehensive treatment of squamous cell cancer of head and neck: Chinese expert consensus 2013. Future Oncol. 10, 1635–1648 (2014).
Sleire, L. et al. Drug repurposing in cancer. Pharmacol. Res. 124, 74–91 (2017).
Gormley, M. et al. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study. PLoS Genet. 17, e1009525 (2021).
Maron, D. J., Fazio, S. & Linton, M. F. Current perspectives on statins. Circulation 101, 207–213 (2000).
Demierre, M.-F., Higgins, P. D., Gruber, S. B., Hawk, E. & Lippman, S. M. Statins and cancer prevention. Nat. Rev. Cancer 5, 930–942 (2005).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011).
Brown, A. J. Cholesterol, statins and cancer. Clin. Exp. Pharmacol. Physiol. 34, 135–141 (2007).
Wong, W. W., Dimitroulakos, J., Minden, M. & Penn, L. HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16, 508–519 (2002).
Denoyelle, C. et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: An in vitro study. Carcinogenesis 22, 1139–1148 (2001).
Kusama, T. et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res. 61, 4885–4891 (2001).
Fridman, W. H., Pagès, F., Sautès-Fridman, C. & Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).
Duffy, S. A. et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer Interdiscip. Int. J. Am. Cancer Soc. 113, 750–757 (2008).
Spector, M. E. et al. Prognostic value of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma. JAMA Otolaryngol. Head Neck Surg. 145, 1012–1019 (2019).
Nguyen, N. et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck 38, 1074–1084 (2016).
Rezaie-Majd, A. et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 22, 1194–1199 (2002).
Lyngdoh, T., Vollenweider, P., Waeber, G. & Marques-Vidal, P. Association of statins with inflammatory cytokines: A population-based Colaus study. Atherosclerosis 219, 253–258 (2011).
Ascer, E. et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177, 161–166 (2004).
Nguyen, T., Khan, A., Liu, Y., El-Serag, H. B. & Thrift, A. P. The association between statin use after diagnosis and mortality risk in patients with esophageal cancer: A retrospective cohort study of United States veterans. Off. J. Am. Coll. Gastroenterol. ACG 113, 1310 (2018).
Zhong, S. et al. Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies. Cancer Treat. Rev. 41, 554–567 (2015).
Mei, Z. et al. Effects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. Int. J. Cancer 140, 1068–1081 (2017).
Mascitelli, L. & Goldstein, M. R. Statin immunomodulation and thyroid cancer. Clin. Endocrinol. 82, 620 (2015).
Beales, I., Vardi, I., Dearman, L. & Broughton, T. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: A case control study. Dis. Esophagus 26, 838–846 (2013).
Nguyen, T., Duan, Z., Naik, A. D., Kramer, J. R. & El-Serag, H. B. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett’s esophagus: A nested case-control study. Gastroenterology 149, 1392–1398 (2015).
Gupta, A. et al. Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer. Oral Oncol. 90, 54–66 (2019).
Nielsen, S. F., Nordestgaard, B. G. & Bojesen, S. E. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367, 1792–1802 (2012).
Kao, L. T., Hung, S. H., Kao, P. F., Liu, J. C. & Lin, H. C. Inverse association between statin use and head and neck cancer: Population-based case-control study in Han population. Head Neck 41, 1193–1198 (2019).
Lebo, N. L., Griffiths, R., Hall, S., Dimitroulakos, J. & Johnson-Obaseki, S. Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma. Head Neck 40, 1697–1706 (2018).
Overhage, J. M., Ryan, P. B., Reich, C. G., Hartzema, A. G. & Stang, P. E. Validation of a common data model for active safety surveillance research. J. Am. Med. Inform. Assoc. 19, 54–60 (2012).
Hripcsak, G. et al. Observational health data sciences and informatics (OHDSI): Opportunities for observational researchers. Stud. Health Technol. Inform. 216, 574–578 (2015).
Ahmadi, N., Peng, Y., Wolfien, M., Zoch, M. & Sedlmayr, M. OMOP CDM can facilitate data-driven studies for cancer prediction: A systematic review. Int. J. Mol. Sci. 23, 11834 (2022).
Millar, J. The need for a global language-SNOMED CT introduction. Stud. Health Technol. Inform. 225, 683–685 (2016).
Zhong, S. et al. Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies. Cancer Treat. Rev. 41, 554–567. https://doi.org/10.1016/j.ctrv.2015.04.005 (2015).
Mei, Z. et al. Effects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. Int. J. Cancer 140, 1068–1081. https://doi.org/10.1002/ijc.30526 (2017).
Byon, C. H. et al. Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4. Lab. Investig. 89, 1221–1228 (2009).
Chan, K. K., Oza, A. M. & Siu, L. L. The statins as anticancer agents. Clin. Cancer Res. 9, 10–19 (2003).
Lee, K. et al. Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. Clin. Exp. Immunol. 161, 298–305 (2010).
Seo, W.-W. et al. Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: A distributed network analysis of 10 real-world databases. Cardiovasc. Diabetol. 21, 1–14 (2022).
Kim, S. et al. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics. Eur. J. Nucl. Med. Mol. Imaging 49, 3547–3556 (2022).
Sundararajan, V. et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J. Clin. Epidemiol. 57, 1288–1294 (2004).
Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 40, 373–383 (1987).
Bannay, A. et al. The best use of the Charlson comorbidity index with electronic health care database to predict mortality. Med. Care 54, 188–194 (2016).
Extermann, M. Measuring comorbidity in older cancer patients. Eur. J. Cancer 36, 453–471 (2000).
Chaudhary, H. et al. Readmission following primary surgery for larynx and oropharynx cancer in the elderly. Laryngoscope 127, 631–641 (2017).
Stordeur, S. et al. Comorbidity in head and neck cancer: Is it associated with therapeutic delay, post-treatment mortality and survival in a population-based study?. Oral Oncol. 102, 104561 (2020).
Xue, X. et al. Testing the proportional hazards assumption in case-cohort analysis. BMC Med. Res. Methodol. 13, 88 (2013).
Mnguni, A. T. et al. The clinical and epidemiological characteristics of a series of patients living with HIV admitted for COVID-19 in a district hospital. BMC Infect. Dis. 23, 123 (2023).
Kleinbaum, D. G., Klein, M., Kleinbaum, D. G. & Klein, M. Kaplan–Meier survival curves and the log-rank test. Surv. Anal. Self-learn. Text 55–96 (2012).
Schuemie, M., Suchard, M. & Ryan, P. CohortMethod: New-user cohort method with large scale propensity and outcome models. 2022. Available from: https://ohdsi.github.io/CohortMethod, https://github.com/OHDSI/CohortMethod.
Schuemie, M., Ryan, P., Shaddox, T. & Suchard, M. SelfControlledCaseSeries: Self-controlled case series. R package version 4.1.0. 2023. Available from: https://github.com/OHDSI/SelfControlledCaseSeries.
Gilbert, J., Schuemie, M. & Ryan, P. SelfControlledCohort: Population-level estimation method that estimates incidence rate comparison of exposed/unexposed time within an exposed cohort. R package version 1.6.0. 2022. Available from: https://github.com/OHDSI/SelfControlledCohort.
Schuemie, M. & Suchard, M. EvidenceSynthesis: Synthesizing causal evidence in a distributed research network. 2023. Available from: https://ohdsi.github.io/EvidenceSynthesis/, https://github.com/OHDSI/EvidenceSynthesis.